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The proteome data provided in this article were acquired from
MCF7 breast cancer cells stimulated with insulin, and were gen-
erated by using a 2D-SCX (strong cation exchange)/RPLC (reversed
phase liquid chromatography) separation protocol followed by
tandem mass spectrometry (MS) detection. To facilitate data re-
processing by more advanced search engines and the extraction of
additional information from already existing ﬁles, both raw and
processed data are provided. The sample preparation, data acqui-
sition and processing protocols are described in detail. The raw
data relate to work published in “Proteome proﬁle of the MCF7
cancer cell line: a mass spectrometric evaluation” (Sarvaiya et al.,
2006) [1] and are made available through the PRIDE (PRoteomics
IDEntiﬁcations)/ProteomeXchange public repository with identi-
ﬁer PRIDE: PXD004051 (“2016 update of the PRIDE database and
tools” (Vizcaino et al., 2016) [2]).
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Chemistry, Biology
ore speciﬁc
subject areaProteomicsvier Inc. This is an open access article under the CC BY license
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H.A. Sarvaiya, I.M. Lazar / Data in Brief 9 (2016) 579–584580ype of data Excel ﬁles, ﬁgures.
ow data was
acquiredData were generated by data-dependent LC-MS/MS analysis using an 1100 HPLC
system (Agilent) interfaced to an LTQ ion trap mass spectrometer (Thermo
Electron).ata format Raw, processed, analyzed.
xperimental
factorsMCF7 breast cancer cells cultured in EMEM with insulin (10 mg/mL) and FBS (10%).xperimental
featuresCells were harvested at 70–80% conﬂuence, lysed in RIPA buffer, digested with
trypsin and analyzed by 2D-SCX/C18 reversed phase nano-LC and ESI-MS/MS.ata source
locationVirginia Tech, Blacksburg, VA 24061, USA.ata accessibility Data are provided in this article and MS RAW and processed ﬁles have been deposited
in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identiﬁer PRIDE [2]: PXD004051 and http://dx.doi.org/DOI:10.6019/PXD004051.Value of the data
 The data provided in this manuscript describe the proteome proﬁle of insulin-stimulated MCF7
breast cancer cells.
 The MS RAW ﬁles can be used to verify the fragmentation pattern of 1þ , 2þ and 3þ non-labeled
peptide ions in a linear ion trap analyzer, to experimentally conﬁrm computational predictions, and
to select precursor-fragment transitions for MRM method development.
 The MS RAW ﬁles can be re-processed with more advanced (or, a combination) of search engines,
to enable the identiﬁcation of additional peptides and proteins, and to conﬁrm the expression of
certain proteins under insulin stimulation conditions.
 The biological processes, functional categories and signaling pathways that were identiﬁed in these
cells can be used as a reference for comparison with other cell stimulation conditions, or for
validating data generated in other laboratories and support the identiﬁcation of putative drug
targets or biomarkers.1. Data
The MCF7 proteome data described in this manuscript include: (a) mass spectrometry RAW ﬁles
deposited in PRIDE; (b) processed RAW ﬁles with the Thermo Electron Discoverer 1.4 software;
(c) processed data with the DAVID (Database for Annotation, Visualization and Integrated Discovery
[3,4]) software package; and (d) processed data with the Cytoscape visualization tool set [5]. Figs. 1–4
provide the sample preparation protocol, representative base-peak chromatograms for the 16 SCX
peptide fractions, the KEGG (Kyoto Encyclopedia of Genes and Genomes [6]) insulin signalingFig. 1. Outline of the MCF7 cell extract processing protocol.
Fig. 2. Representative base-peak chromatograms for 16 SCX peptide fractions generated from MCF7 cell extracts. The LC and
MS systems were operated independently of each other, with a window of 1–5 min for turning on the MS data acquisition
after the LC separation start. Most peptides eluted in fractions 4–15. Fractions 1 (SCX wash), 2, 3 and 16 contained salts, traces
of detergents and contaminants from sample preparation, and only few peptides.
Fig. 3. KEGG pathway for insulin signaling. Proteins identiﬁed in the MCF7 cell extract are marked on the diagram.
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Fig. 4. Cytoscape-generated protein-protein interaction network for identiﬁed insulin signaling proteins.
H.A. Sarvaiya, I.M. Lazar / Data in Brief 9 (2016) 579–584582pathway with identiﬁable proteins marked in red, and a Cytoscape-built protein–protein interaction
network encompassing 34 insulin signaling proteins (see also link to interactive network).
Supplementary Tables 1 and 2 provide Excel spreadsheets with lists of proteins (1898) and peptides
(6802 unique, 12522 PSMs). Supplementary Tables 3 and 4 encompass the KEGG pathways and the
GO (Gene Ontology) and functional annotation charts generated with DAVID. Supplementary Table 5
provides the list of interactions associated with the 34 insulin signaling proteins generated with
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins [7]).2. Experimental design, materials and methods
2.1. Cell culture
MCF7 breast cancer cells were cultured in EMEM with FBS (10%) and insulin (10 mg/mL) at 37 °C in
an incubator with 5% CO2. At 70–80% conﬂuence the cells were detached by trypsinization, harvested
and stored in a freezer at 80 °C.
2.2. Cell processing
The cells were lysed by rocking with RIPA buffer supplemented with protease and phosphatase
inhibitors for 2 h at 4 °C. The ﬁnal composition of the lysis solution was: 1 mL RIPA buffer, 100 mL
protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin,
1.5 mM pepstatin A, 1.4 mM E-64), 100 mL NaF (100 mM), 50 mL Na3VO4 (200 mM) and 8.75 mL of ice
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the supernatant was measured with the Bradford assay. The cell extract (1 mL containing 3 mg of
proteins) was reduced with DTT (4.5 mM) in the presence of urea (8 M) for 1 h at 60 °C. The protein
solution was then diluted 10 fold with NH4HCO3 (50 mM) and subjected to enzymatic digestion with
trypsin at a protein:enzyme ratio of 50:1 w/w, overnight at 37 °C. The digestion reaction was quen-
ched with 10 mL TFA/mL protein digest solution, and 300 mg of the protein digest was desalted with
SPEC-PTC18 solid phase extraction tips. The sample was concentrated to a ﬁnal concentration of
4 mg/mL with a vacuum centrifuge, and stored at 20 °C until further analysis by shotgun 2D-SCX/
LC-ESI-MS/MS.
2.3. 2D-SCX/nano-ESI-MS/MS
SCX prefractionation was accomplished with an 1100 HPLC system (Agilent) on a Zorbax Bio SCX
Series II column (0.8 mm i.d.5 cm column, Agilent) operated at 20 mL/min eluent ﬂow. The eluent
was H2O/CH3CN (95:5 v/v) supplemented with 0.1% HCOOH (solvent A), or 0.1% HCOOH and 500 mM
NaCl (solvent B). The sample (16 mL injection containing 64 mg protein digest) was eluted from the
SCX column in 16 fractions by a gradient consisting of: 100% A (0–5 min), 0–5% B (5–5.1 min), 5–20% B
(5.1–35 min), 20–100% B (35–40 min), 100% B (40–50 min), 100 to 0% B (50–50.1 min) and 100% A
(50.1–60 min). The ﬁrst wash step (5 min) generated fraction 1. Fractions 2–15 were collected each for
3 min during the salt gradient. Fraction 16 was collected for 10 min at an eluent composition of
mainly 100% B. Reversed phase nano-LC separations were performed with home-built capillary col-
umns (100 mm i.d.12 cm fused silica capillaries) packed with Zorbax SB-C18 (5 mm) particles
(Agilent). The nano-LC columnwas ﬁtted with a 1 cm long nanospray emitter prepared from a fused
silica capillary (20 mm i.d.90 mm o.d.). The Agilent 1100 micro-HPLC system was modiﬁed with a
home-built split/splitless setup to allow for the generation of solvent gradients in the nanoliter/min
ﬂow regime. Each SCX fraction was loaded separately on the nano-LC column (40 mL), and eluted by
an eluent gradient at 160–180 nL/min. Solvent A was prepared from H2O/CH3CN (95:5 v/v)þ0.01%
TFA, and solvent B from H2O/CH3CN (20:80 v/v)þ0.01% TFA. The gradient consisted of: 0–10% B (0–
1 min), 10–45% B (1–95 min), 45–60% B (95–110 min), 60–100% B (110–115 min), 100%B
(115–120 min), 100 to 0% B (120–121 min) and 100% A (121–150 min).
2.4. Mass spectrometry
An LTQ linear ion trap mass spectrometer (Thermo Electron) was used for detection. Data acqui-
sition occurred in data-dependent mode using 1 MS scan (5 microscans averaged) followed by 1 zoom
scan (5 microscans averaged) and 1 MS2 on the top 5 most intense peaks. The zoom scan window was
75 m/z. Dynamic exclusion parameters were set at repeat count 1, repeat duration 30 s, exclusion list
size 200, exclusion duration 60 s and exclusion mass width 71.5 m/z. Precursor ion fragmentation
occurred by setting the collision induced dissociation (CID) parameters at isolation width of 3m/z,
normalized collision energy 35%, activation Q 0.25 and activation time 30 ms.
2.5. Data processing
Raw data were analyzed with the Discoverer 1.4 software package (Thermo Electron) by using a
Homo sapiens database with 20,199 entries downloaded from UniProt (January 2015). The database
search parameters included: chemical and posttranslational modiﬁcations were not allowed, mini-
mum and maximum peptide length was 6 and 144 amino acids, respectively, only fully tryptic
fragments were considered for peptide matching, the number of allowed missed cleavage sites was 2,
the precursor ion tolerance was 2 amu, the fragment ion tolerance was 1 amu, and the relaxed and
strict false discovery rates (FDRs) were set at 3% and 1%, respectively. The quality of the data at the
peptide level is veriﬁable from multiple tandem MS hits/peptide. The reliability of protein identiﬁ-
cations can be inferred from the number of unique peptide hits/protein and FDRs set per user's
preference and choice of search engine. The list of identiﬁed proteins was uploaded in DAVID to
identify the KEGG signaling pathways and to generate the GO and functional annotation charts. All
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were uploaded in STRING to extract the known protein–protein interactions related to this set of
proteins. This list of interactions was uploaded to Cytoscape 3.4.0 to visualize the network of inter-
actions in a degree sorted circle layout.
2.6. Reagents
Methanol and acetonitrile (HPLC grade) were purchased from Fisher Scientiﬁc, and deionized water
(18 MΩ-cm) was generated in-house with a MilliQ ultrapure water system. MCF7 cells and cell culture
reagents (EMEM, FBS, insulin, trypsin/EDTA) were purchased from ATCC, RIPA lysis buffer from Upstate,
sequencing grade modiﬁed trypsin from Promega, protease inhibitors (NaF, Na3VO4) and other reagents
(NaCl, TFA, HCOOH, TrisHCL, urea and DTT) from Sigma, and NH4HCO3 from Aldrich.Acknowledgments
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